TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, is pleased to announce that the Company has entered into an evaluation and exclusive option…


Previous articleBraxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
Next articleatai Life Sciences to Participate in November Investor Events & Healthcare Conferences